MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

MDT

84

-0.14%↓

VEEV

225.63

-0.54%↓

A

106.87

+0.63%↑

WBA

10.96

-0.36%↓

CHE

562.2

+1.12%↑

Search

IQVIA Holdings Inc

Gesloten

SectorGezondheidszorg

150.05

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

148.4

Max

151.61

Belangrijke statistieken

By Trading Economics

Inkomsten

152M

437M

Verkoop

58M

4B

K/W

Sectorgemiddelde

19.199

57.333

EPS

3.12

Winstmarge

11.041

Werknemers

88,000

EBITDA

162M

1B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+41.57% upside

Dividenden

By Dow Jones

Volgende Winsten

6 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-11B

26B

Vorige openingsprijs

150.05

Vorige sluitingsprijs

150.05

Technische score

By Trading Central

Vertrouwen

Very Strong Bullish Evidence

IQVIA Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 apr 2025, 23:55 UTC

Marktinformatie

Oil Edges Higher Amid Hopes for Easing U.S.-China Trade Tensions -- Market Talk

27 apr 2025, 23:47 UTC

Marktinformatie

Gold Falls Amid Dollar Strength, Signs of Easing U.S.-China Trade Tensions -- Market Talk

27 apr 2025, 23:42 UTC

Marktinformatie

Nikkei May Rise as Fears About U.S.-China Tensions Ebb -- Market Talk

27 apr 2025, 23:12 UTC

Winsten

Sinopharm Group 1Q Rev CNY141.66B Vs. CNY147.27B >1099.HK

27 apr 2025, 23:12 UTC

Winsten

Sinopharm Group 1Q Net CNY1.46B Vs. Net CNY1.42B >1099.HK

27 apr 2025, 20:41 UTC

Winsten

Pharmaron Beijing 1Q Net CNY305.58M Vs. Net CNY230.56M >300759.SZ

27 apr 2025, 20:41 UTC

Winsten

Pharmaron Beijing: Higher Contributions From Laboratory Services Among Factors Supporting Results> 300759.SZ

27 apr 2025, 20:41 UTC

Winsten

Pharmaron Beijing 1Q Rev CNY3.10B Vs. CNY2.67B >300759.SZ

27 apr 2025, 18:41 UTC

Top Nieuws

Bessent Doesn't Know If Trump and Xi Have Talked on Trade -- Barrons.com

27 apr 2025, 11:00 UTC

Top Nieuws

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

27 apr 2025, 05:41 UTC

Winsten

China Everbright Bank 1Q Net CNY12.46B Vs. Net CNY12.43B >601818.SH

27 apr 2025, 05:41 UTC

Winsten

China Everbright Bank: Lower Net Interest Income Weighed on Operating Income>601818.SH

27 apr 2025, 05:41 UTC

Winsten

China Everbright Bank 1Q Operating Income CNY33.10B Vs. CNY34.49B>601818.SH

27 apr 2025, 05:41 UTC

Winsten

China Everbright Bank 1Q Impairment Loss on Credit Assets Was CNY8.49B; Down 15.6% on Year>601818.SH

27 apr 2025, 05:41 UTC

Winsten

China Everbright Bank 1Q Operating Expenses Was CNY9.15B; Down 3.2%>601818.SH

27 apr 2025, 05:41 UTC

Winsten

China Everbright Bank 1Q Net Interst Income Was CNY22.54B; Down 6.8% on Year>601818.SH

27 apr 2025, 05:34 UTC

Winsten

Chongqing Rural Commercial Bank: 1Q Results Supported by Higher Net Interest Income>3618.HK

27 apr 2025, 05:34 UTC

Winsten

Chongqing Rural Commercial Bank 1Q Operating Income CNY7.22B Vs. CNY7.13B>3618.HK

27 apr 2025, 05:34 UTC

Winsten

Chongqing Rural Commercial Bank 1Q Net CNY3.75B Vs. Net CNY3.52B >3618.HK

27 apr 2025, 05:29 UTC

Winsten

China Shenhua Energy: Results Weighed by Fall in Selling Prices of Coal >1088.HK

27 apr 2025, 05:29 UTC

Winsten

China Shenhua Energy 1Q Net CNY13.37B Vs. Net CNY17.76B >1088.HK

27 apr 2025, 05:29 UTC

Winsten

China Shenhua Energy 1Q Rev CNY69.59B Vs. CNY87.65B >1088.HK

27 apr 2025, 05:29 UTC

Winsten

China Shenhua Energy: Lower Revenue From Electricity Sales Also Hurt Results >1088.HK

27 apr 2025, 05:21 UTC

Winsten

CMOC Group 1Q Net CNY3.95B Vs. Net CNY2.07B >3993.HK

27 apr 2025, 05:21 UTC

Winsten

CMOC Group: Cost Cuts Also Among Factors that Boosted 1Q Net >3993.HK

27 apr 2025, 05:21 UTC

Winsten

CMOC Group 1Q Rev CNY46.01B Vs. CNY46.12B >3993.HK

27 apr 2025, 05:21 UTC

Winsten

CMOC Group: Increase in Prices of Copper, Cobalt Supported Results>3993.HK

27 apr 2025, 03:00 UTC

Top Nieuws

Chinese Manufacturers Are Scouring the World for New Buyers -- WSJ

27 apr 2025, 00:30 UTC

Top Nieuws

Meta's 'Digital Companions' Will Talk Sex With Users -- Even Children -- WSJ

27 apr 2025, 00:30 UTC

Top Nieuws

Meta's 'Digital Companions' Will Talk Sex With Users -- Even Children -- WSJ -2-

Peer Vergelijking

Prijswijziging

IQVIA Holdings Inc Prognose

Koersdoel

By TipRanks

41.57% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 212.75 USD  41.57%

Hoogste 270 USD

Laagste 160 USD

Gebaseerd op 17 Wall Street-analisten die 12-maands prijsdoelen bieden voor IQVIA Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

17 ratings

11

Buy

6

Hold

0

Sell

Technische score

By Trading Central

143.5 / 150.68Steun & Weerstand

Korte Termijn

Very Strong Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.